A novel chemically modified curcumin "normalizes" Wound-healing in rats with experimentally induced type i diabetes: Initial studies

Yazhou Zhang, Steve A. McClain, Hsi Ming Lee, Muna S. Elburki, Huiwen Yu, Ying Gu, Yu Zhang, Mark Wolff, Francis Johnson, Lorne M. Golub

Research output: Contribution to journalArticle

Abstract

Introduction. Impaired wound-healing in diabetics can lead to life-threatening complications, such as limb amputation, associated in part with excessive matrix metalloproteinase- (MMP-) mediated degradation of collagen and other matrix constituents. In the current study, a novel triketonic chemically modified curcumin, CMC2.24, was tested for efficacy in healing of standardized skin wounds in streptozotocin-induced diabetic rats. Initially, CMC2.24 was daily applied topically at 1% or 3% concentrations or administered systemically (oral intubation; 30 mg/kg); controls received vehicle treatment only. Over 7 days, the diabetics exhibited impaired wound closure, assessed by gross and histologic measurements, compared to the nondiabetic controls. All drug treatments significantly improved wound closure with efficacy ratings as follows: 1% 2.24 > systemic 2.24 > 3% 2.24 with no effect on the severe hyperglycemia. In subsequent experiments, 1% CMC2.24 "normalized" wound-healing in the diabetics, whereas 1% curcumin was no more effective than 0.25% CMC2.24, and the latter remained 34% worse than normal. MMP-8 was increased 10-fold in the diabetic wounds and topically applied 1% (but not 0.25%) CMC2.24 significantly reduced this excessive collagenase-2; MMP-13/collagenase-3 did not show significant changes. Additional studies indicated efficacy of 1% CMC2.24 over more prolonged periods of time up to 30 days.

Original languageEnglish (US)
Article number5782904
JournalJournal of Diabetes Research
Volume2016
DOIs
StatePublished - 2016

Fingerprint

Curcumin
Type 1 Diabetes Mellitus
Wound Healing
Matrix Metalloproteinase 8
Matrix Metalloproteinase 13
Wounds and Injuries
Streptozocin
Matrix Metalloproteinases
Amputation
Intubation
Hyperglycemia
1,7-bis(4-hydroxyphenyl)-4-N-phenylaminocarbonylhepta-1,6-dien-3,5-dione
Collagen
Extremities
Skin
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

A novel chemically modified curcumin "normalizes" Wound-healing in rats with experimentally induced type i diabetes : Initial studies. / Zhang, Yazhou; McClain, Steve A.; Lee, Hsi Ming; Elburki, Muna S.; Yu, Huiwen; Gu, Ying; Zhang, Yu; Wolff, Mark; Johnson, Francis; Golub, Lorne M.

In: Journal of Diabetes Research, Vol. 2016, 5782904, 2016.

Research output: Contribution to journalArticle

Zhang, Yazhou ; McClain, Steve A. ; Lee, Hsi Ming ; Elburki, Muna S. ; Yu, Huiwen ; Gu, Ying ; Zhang, Yu ; Wolff, Mark ; Johnson, Francis ; Golub, Lorne M. / A novel chemically modified curcumin "normalizes" Wound-healing in rats with experimentally induced type i diabetes : Initial studies. In: Journal of Diabetes Research. 2016 ; Vol. 2016.
@article{bc8dad8dcc3840269955f81f3cf30578,
title = "A novel chemically modified curcumin {"}normalizes{"} Wound-healing in rats with experimentally induced type i diabetes: Initial studies",
abstract = "Introduction. Impaired wound-healing in diabetics can lead to life-threatening complications, such as limb amputation, associated in part with excessive matrix metalloproteinase- (MMP-) mediated degradation of collagen and other matrix constituents. In the current study, a novel triketonic chemically modified curcumin, CMC2.24, was tested for efficacy in healing of standardized skin wounds in streptozotocin-induced diabetic rats. Initially, CMC2.24 was daily applied topically at 1{\%} or 3{\%} concentrations or administered systemically (oral intubation; 30 mg/kg); controls received vehicle treatment only. Over 7 days, the diabetics exhibited impaired wound closure, assessed by gross and histologic measurements, compared to the nondiabetic controls. All drug treatments significantly improved wound closure with efficacy ratings as follows: 1{\%} 2.24 > systemic 2.24 > 3{\%} 2.24 with no effect on the severe hyperglycemia. In subsequent experiments, 1{\%} CMC2.24 {"}normalized{"} wound-healing in the diabetics, whereas 1{\%} curcumin was no more effective than 0.25{\%} CMC2.24, and the latter remained 34{\%} worse than normal. MMP-8 was increased 10-fold in the diabetic wounds and topically applied 1{\%} (but not 0.25{\%}) CMC2.24 significantly reduced this excessive collagenase-2; MMP-13/collagenase-3 did not show significant changes. Additional studies indicated efficacy of 1{\%} CMC2.24 over more prolonged periods of time up to 30 days.",
author = "Yazhou Zhang and McClain, {Steve A.} and Lee, {Hsi Ming} and Elburki, {Muna S.} and Huiwen Yu and Ying Gu and Yu Zhang and Mark Wolff and Francis Johnson and Golub, {Lorne M.}",
year = "2016",
doi = "10.1155/2016/5782904",
language = "English (US)",
volume = "2016",
journal = "Journal of Diabetes Research",
issn = "2314-6745",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - A novel chemically modified curcumin "normalizes" Wound-healing in rats with experimentally induced type i diabetes

T2 - Initial studies

AU - Zhang, Yazhou

AU - McClain, Steve A.

AU - Lee, Hsi Ming

AU - Elburki, Muna S.

AU - Yu, Huiwen

AU - Gu, Ying

AU - Zhang, Yu

AU - Wolff, Mark

AU - Johnson, Francis

AU - Golub, Lorne M.

PY - 2016

Y1 - 2016

N2 - Introduction. Impaired wound-healing in diabetics can lead to life-threatening complications, such as limb amputation, associated in part with excessive matrix metalloproteinase- (MMP-) mediated degradation of collagen and other matrix constituents. In the current study, a novel triketonic chemically modified curcumin, CMC2.24, was tested for efficacy in healing of standardized skin wounds in streptozotocin-induced diabetic rats. Initially, CMC2.24 was daily applied topically at 1% or 3% concentrations or administered systemically (oral intubation; 30 mg/kg); controls received vehicle treatment only. Over 7 days, the diabetics exhibited impaired wound closure, assessed by gross and histologic measurements, compared to the nondiabetic controls. All drug treatments significantly improved wound closure with efficacy ratings as follows: 1% 2.24 > systemic 2.24 > 3% 2.24 with no effect on the severe hyperglycemia. In subsequent experiments, 1% CMC2.24 "normalized" wound-healing in the diabetics, whereas 1% curcumin was no more effective than 0.25% CMC2.24, and the latter remained 34% worse than normal. MMP-8 was increased 10-fold in the diabetic wounds and topically applied 1% (but not 0.25%) CMC2.24 significantly reduced this excessive collagenase-2; MMP-13/collagenase-3 did not show significant changes. Additional studies indicated efficacy of 1% CMC2.24 over more prolonged periods of time up to 30 days.

AB - Introduction. Impaired wound-healing in diabetics can lead to life-threatening complications, such as limb amputation, associated in part with excessive matrix metalloproteinase- (MMP-) mediated degradation of collagen and other matrix constituents. In the current study, a novel triketonic chemically modified curcumin, CMC2.24, was tested for efficacy in healing of standardized skin wounds in streptozotocin-induced diabetic rats. Initially, CMC2.24 was daily applied topically at 1% or 3% concentrations or administered systemically (oral intubation; 30 mg/kg); controls received vehicle treatment only. Over 7 days, the diabetics exhibited impaired wound closure, assessed by gross and histologic measurements, compared to the nondiabetic controls. All drug treatments significantly improved wound closure with efficacy ratings as follows: 1% 2.24 > systemic 2.24 > 3% 2.24 with no effect on the severe hyperglycemia. In subsequent experiments, 1% CMC2.24 "normalized" wound-healing in the diabetics, whereas 1% curcumin was no more effective than 0.25% CMC2.24, and the latter remained 34% worse than normal. MMP-8 was increased 10-fold in the diabetic wounds and topically applied 1% (but not 0.25%) CMC2.24 significantly reduced this excessive collagenase-2; MMP-13/collagenase-3 did not show significant changes. Additional studies indicated efficacy of 1% CMC2.24 over more prolonged periods of time up to 30 days.

UR - http://www.scopus.com/inward/record.url?scp=84967108920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84967108920&partnerID=8YFLogxK

U2 - 10.1155/2016/5782904

DO - 10.1155/2016/5782904

M3 - Article

C2 - 27190999

AN - SCOPUS:84967108920

VL - 2016

JO - Journal of Diabetes Research

JF - Journal of Diabetes Research

SN - 2314-6745

M1 - 5782904

ER -